PEPTIDES A
105
0 days B
14 days
1 months
3 months
4 months
Figure 3: CameraScan images at different time points of volunteers treated with the active ingredient before and after BTA injection. A) With surprise expression. B) With concern expression
resulted in a less significant reduction, thereby maintaining reduced wrinkle visibility for a longer duration. Furthermore, trend calculations for the
average of the three areas indicated that the peptide helped delay the diminishing effects of BTA by nearly eight weeks. Figure 3 provides two examples of the forehead and frown wrinkles in volunteers of the active group with surprise and concern expressions, showing a remarkable improvement and sustained effect throughout the 4-month period.
Prolonged skin smoothness with the active peptide ingredient treatment Skin roughness (Ra) was analyzed using Primos software (Canfield). 3D microphotographs of the forehead, frown, and crow’s feet areas were obtained using the fringe projection- based imaging system (Primos, Canfield). For the three areas analyzed, the group of
volunteers that applied the active formulation showed a continued improvement in skin roughness over time (Figure 4). Although the effects of BTA progressively diminished by the fourth month, the volunteers who used the
12 10 8 6 4 2 0
-2 -4
1 month
active formulation maintained smoother skin compared to the placebo group. Additionally, the improvement in skin
roughness in the forehead and frown areas with the peptide treatment surpassed the effects of BTA alone, indicating an enhancing effect of the active peptide on the toxin injections. An example image of a volunteer from
the active group (Figure 5), illustrates the improvement in skin roughness, achieving better homogeneity in skin texture.
Reduced prominence of forehead and frown wrinkles To evaluate the mean length of prominent wrinkles, 3D facial images were captured using the 3D LifeViz Infinity system (Quantificare). The LifeVizAPP software (Quantificare) was employed to highlight the most prominent wrinkles on the forehead and frown regions. The mean length of these wrinkles was analyzed using proprietary computer vision techniques. This process involved the k-means
clustering method to segment wrinkle pixels 15 10 10 5 5 1.1% -1.0% 3 months -1.0% -7.1% -10 4 months 1 month 3 months 4 months -5 1 month 3 months 4 months
Figure 4: Variation (%) in the skin roughness parameter with time for the different treatments. versus 14 days (Forehead: l.s. p<0.1 versus placebo at four months. Frown: *p<0.05 versus placebo at 1 and four months). Wilcoxon or Student’s t test was used after checking the normality distributions by a Shapiro-Wilk test
www.personalcaremagazine.com October 2025 PERSONAL CARE 0 -5 -3.1% -2.4% 0 -0.7% 5.8% 5.9%
from the skin. The wrinkle skeletons were then identified by refining the segmented objects to single lines. The average length of these wrinkle skeletons was measured and divided by the total number of detected wrinkles to determine the mean length of wrinkles. The most prominent wrinkles showed a
visible reduction in their length after BTA treatment. However, it was observed that volunteers who also applied the active formulation maintained the improvement in mean wrinkle length compared to those using the placebo formulation after four months of BTA injections (Figure 6A). Figure 6B shows an example of 3D images
of a volunteer treated with the active peptide. After 14 days of treatment with the toxin, a clear reduction in wrinkle length is evident, and at the end of the treatment with the active ingredient, these wrinkles continue to appear reduced on the forehead and frown, with a lesser appearance than before the BTA injections.
Conclusion In response to the increasing demand for
■ Placebo ■ 5% Argireline Amplified peptide solution 15
Roughness (Ra) variation on forehead vs. 14 days (%)
Roughness (Ra) variation on frown vs. 14 days (%)
Roughness (Ra) variation on crow's feet vs. 14 days (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
